Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

116.28 -0.17 (-0.15%)

Delayed Quote Updated: 4:00 PM EDT, Oct 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

22 23 Next >

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Strong Affordable Growth Pick with Solid Fundamentals ↗

July 30, 2025

CORCEPT THERAPEUTICS (CORT) offers strong growth potential with fair valuations, solid profitability, and a healthy balance sheet, making it an attractive pick for Affordable Growth investors.

Via Chartmill

What To Expect From Corcept’s (CORT) Q2 Earnings

July 29, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings this Thursday after the bell. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 24, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential ↗

July 22, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong revenue growth, high profitability, and a promising technical setup, making it a noteworthy candidate for growth investors.

Via Chartmill

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years ↗

July 21, 2025

Via Benzinga

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit World Trade

What's Driving the Market Sentiment Around Corcept Therapeutics? ↗

July 17, 2025

Via Benzinga

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

July 14, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

3 High-Flying Stocks Skating on Thin Ice

July 14, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - A Promising Affordable Growth Stock ↗

July 09, 2025

CORCEPT THERAPEUTICS (NASDAQ:CORT) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks.

Via Chartmill

1 Cash-Producing Stock Worth Your Attention and 2 to Ignore

July 07, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Here's How Much $100 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth Today ↗

July 04, 2025

Via Benzinga

3 Russell 2000 Stocks in Hot Water

June 30, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential ↗

June 28, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong growth fundamentals and a bullish technical setup, making it a candidate for growth investors. High revenue growth, profitability, and a debt-free...

Via Chartmill

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

June 23, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

June 16, 2025

Via Benzinga

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study ↗

June 05, 2025

Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in Phase 3.

Via Benzinga

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

June 05, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

2 Profitable Stocks to Target This Week and 1 to Avoid

June 05, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

June 02, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear Of

June 02, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today ↗

May 30, 2025

Via Benzinga

1 Growth Stock with All-Star Potential and 2 to Avoid

May 26, 2025

Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID...

Via StockStory

Topics Artificial Intelligence

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential ↗

May 22, 2025

CORCEPT THERAPEUTICS (NASDAQ:CORT) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch. High revenue growth, profitability, and a debt-free balance sheet support...

Via Chartmill

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

May 21, 2025

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed

May 19, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the other hand, the company’s...

Via StockStory

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years ↗

May 12, 2025

Via Benzinga

Looking for growth without the hefty price tag? Consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT). ↗

May 10, 2025

Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.